Capricor Therapeutics (NASDAQ:CAPR) Trading 12.2% Higher – Time to Buy?

Capricor Therapeutics, Inc. (NASDAQ:CAPR)’s stock price traded up 12.2% during mid-day trading on Wednesday . The stock traded as high as $25.58 and last traded at $25.8510. 921,906 shares changed hands during trading, a decline of 23% from the average session volume of 1,196,288 shares. The stock had previously closed at $23.03.

Analyst Upgrades and Downgrades

CAPR has been the subject of several recent research reports. Oppenheimer raised their target price on shares of Capricor Therapeutics from $22.00 to $54.00 and gave the company an “outperform” rating in a report on Monday, December 8th. iA Financial set a $48.00 price objective on shares of Capricor Therapeutics in a research note on Wednesday, December 3rd. Maxim Group lifted their price objective on Capricor Therapeutics from $25.00 to $50.00 and gave the stock a “buy” rating in a research report on Thursday, December 4th. Alliance Global Partners reiterated a “buy” rating on shares of Capricor Therapeutics in a report on Wednesday, December 3rd. Finally, Piper Sandler reissued an “overweight” rating and set a $45.00 price target (up previously from $20.00) on shares of Capricor Therapeutics in a research report on Wednesday, December 10th. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $40.82.

Capricor Therapeutics Trading Up 10.7%

The business has a 50 day simple moving average of $25.49 and a two-hundred day simple moving average of $13.98. The company has a market cap of $1.17 billion, a PE ratio of -14.16 and a beta of 0.38.

Institutional Trading of Capricor Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its stake in shares of Capricor Therapeutics by 16.1% during the 4th quarter. Vanguard Group Inc. now owns 2,561,880 shares of the biotechnology company’s stock valued at $73,936,000 after acquiring an additional 355,161 shares during the last quarter. Suvretta Capital Management LLC purchased a new stake in Capricor Therapeutics in the fourth quarter valued at approximately $51,533,000. Tang Capital Management LLC purchased a new stake in Capricor Therapeutics in the fourth quarter valued at approximately $49,062,000. RA Capital Management L.P. acquired a new position in Capricor Therapeutics during the fourth quarter worth approximately $43,516,000. Finally, Geode Capital Management LLC raised its stake in Capricor Therapeutics by 5.8% during the fourth quarter. Geode Capital Management LLC now owns 1,017,332 shares of the biotechnology company’s stock worth $29,367,000 after purchasing an additional 55,766 shares during the period. 21.68% of the stock is owned by institutional investors and hedge funds.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.